Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Pharmaceutical Co Ltd Takeda currently holds 3,755,583 shares of Ovid Therapeutics Inc. (OVID), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Pharmaceutical Co Ltd Takeda has been a net seller of OVID stock. They have purchased $5.0M and sold $205.9M worth of shares.
Pharmaceutical Co Ltd Takeda's most recent insider trade was on Sep 17, 2025, when they sold 6,724,000 shares at $1.95 per share.
Pharmaceutical Co Ltd Takeda serves as Executive at Ovid Therapeutics Inc. (OVID). They have executed 65 insider transactions totaling $210.9M over their tenure at the company.
Pharmaceutical Co Ltd Takeda holds the position of Executive at Ovid Therapeutics Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 7 years and currently hold a stake valued at $0.
Pharmaceutical Co Ltd Takeda has shown a selling trading pattern, with $5.0M in total purchases and $205.9M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Pharmaceutical Co Ltd Takeda was on Jan 24, 2024, when they sold $30.0M worth of PHAT shares. This transaction involved 3,703,703 shares at $8.10 per share.
Pharmaceutical Co Ltd Takeda currently owns 3,755,583 shares of Ovid Therapeutics Inc. (OVID), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Pharmaceutical Co Ltd Takeda's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Pharmaceutical Co Ltd Takeda has 65 Form 4 filings on record as an insider at Ovid Therapeutics Inc..
Set alerts for Pharmaceutical Co Ltd Takeda and 40,000+ other insiders.